Princeton, New Jersey, October 13, 2010 - Sandoz announced today the launch of pramipexole dihydrochloride tablets, a generic equivalent of Mirapex®, in the US. Pramipexole dihydrochloride tablets are ...

February 23, 2010 — The US Food and Drug Administration (FDA) has approved a new once-daily formulation of pramipexole dihydrochloride (Mirapex ER tablets, Boehringer Ingelheim Pharmaceuticals, Inc) ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

Pramipexole dihydrochloride extended-release 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, 4.5mg; tabs. Swallow whole. May take with food. Initially 0.375mg once daily ...

The tablets are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30 Dr Reddy’s Laboratories (DRL) has launched Pramipexole dihydrochloride extended-release tablets ...

Pramipexole is a prescription drug. It comes in immediate-release and extended-release oral tablets. Pramipexole oral tablets are available as the brand-name drugs Mirapex and Mirapex ER. Pramipexole ...

Dr. Reddy’s Laboratories announced the launch of Pramipexole Dihydrochloride Extended-Release Tablets, the generic version of Boehringer Ingelheim’s Mirapex ER. Mirapex ER is a non-ergot dopamine ...

Zydus Pharmaceuticals, Inc., a wholly owned subsidiary of Cadila Healthcare has received the final approval from the USFDA to market pramipexole Dihydrochloride extended-release tablets in strengths ...

The Union Budget contains details about the estimated receipts and the expenditure of the government for a particular fiscal year. The Budget is allotted for the upcoming fiscal year, which runs from ...

RIDGEFIELD, Conn., Feb. 22 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole ...